Last updated: 23 May 2023 at 8:09am EST

Dr. Paul R. Kirchgraber M.D. Net Worth




The estimated Net Worth of Paul R Kirchgraber is at least $8.18 Миллион dollars as of 19 May 2023. Dr Kirchgraber owns over 4,300 units of Labcorp stock worth over $3,764,629 and over the last 5 years he sold LH stock worth over $3,017,225. In addition, he makes $1,397,568 as Exec. VP & CEO of Covance Drug Devel. at Labcorp.

Dr D LH stock SEC Form 4 insiders trading

Dr has made over 19 trades of the Labcorp stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 4,300 units of LH stock worth $784,793 on 19 May 2023.

The largest trade he's ever made was selling 8,000 units of Labcorp stock on 21 February 2023 worth over $2,004,640. On average, Dr trades about 1,082 units every 44 days since 2019. As of 19 May 2023 he still owns at least 17,246 units of Labcorp stock.

You can see the complete history of Dr Kirchgraber stock trades at the bottom of the page.





Dr. Paul R. Kirchgraber M.D. biography

Dr. Paul R. Kirchgraber M.D. is the Exec. VP & CEO of Covance Drug Devel. at Labcorp.

What is the salary of Dr D?

As the Exec. VP & CEO of Covance Drug Devel. of Labcorp, the total compensation of Dr D at Labcorp is $1,397,568. There are 8 executives at Labcorp getting paid more, with Glenn Eisenberg having the highest compensation of $8,822,760.



How old is Dr D?

Dr D is 59, he's been the Exec. VP & CEO of Covance Drug Devel. of Labcorp since . There are 9 older and 15 younger executives at Labcorp. The oldest executive at Labcorp Holdings Inc. is Jean-Luc Belingard, 71, who is the Independent Director.

What's Dr D's mailing address?

Paul's mailing address filed with the SEC is 531, South Spring Street, Burlington, Alamance County, North Carolina, 27215, United States.

Insiders trading at Labcorp

Over the last 19 years, insiders at Labcorp have traded over $236,972,149 worth of Labcorp stock and bought 10,666 units worth $1,520,331 . The most active insiders traders include Mahon Thomas P Mac, Garheng Kong и David P King. On average, Labcorp executives and independent directors trade stock every 11 days with the average trade being worth of $2,652,442. The most recent stock trade was executed by Der Vaart Sandra D Van on 19 August 2024, trading 2,000 units of LH stock currently worth $454,100.



What does Labcorp do?

recognized for our innovation, quality, and customer convenience, labcorp delivers timely, accurate results for improved patient care. with scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology, labcorp performs more than one million tests on approximately 400,000 samples each day. labcorp is a pioneer in applying advances in medicine and science to laboratory testing, with more than 35 years of experience in serving physicians and their patients. labcorp operates a sophisticated laboratory network, with corporate headquarters in burlington, nc, and more than 34,000 employees worldwide. our more than 220,000 clients include physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies. laboratory corporation of america holdings is listed on the new york stock exchange (nyse) under ticker symbol lh.



Complete history of Dr Kirchgraber stock trades at Labcorp

инсайдер
Транзакция
Транзакция
Общая стоимость
Paul R Kirchgraber
Исполнительный директор и Covance Drug Development
Реализация опциона $784,793
19 May 2023
Paul R Kirchgraber
Исполнительный директор и Covance Drug Development
Продажа $2,004,640
21 Feb 2023
Paul R Kirchgraber
Исполнительный директор и Covance Drug Development
Реализация опциона $118,765
11 Feb 2023
Paul R Kirchgraber
Исполнительный директор и Covance Drug Development
Реализация опциона $139,630
4 Feb 2023
Paul R Kirchgraber
Исполнительный директор и Covance Drug Development
Реализация опциона $112,961
2 Feb 2023
Paul R Kirchgraber
Исполнительный директор и Covance Drug Development
Реализация опциона $446,678
1 Nov 2022
Paul R Kirchgraber
Исполнительный директор и Covance Drug Development
Реализация опциона $87,574
11 Feb 2022
Paul R Kirchgraber
Исполнительный директор и Covance Drug Development
Реализация опциона $155,389
4 Feb 2022
Paul R Kirchgraber
Исполнительный директор и Covance Drug Development
Реализация опциона $121,019
2 Feb 2022
Paul R Kirchgraber
Исполнительный директор и Covance Drug Development
Реализация опциона $579,581
1 Nov 2021
Paul R Kirchgraber
Исполнительный директор и Covance Drug Development
Продажа $691,375
6 May 2021
Paul R Kirchgraber
Исполнительный директор и Covance Drug Development
Реализация опциона $255,227
3 Apr 2021
Paul R Kirchgraber
Исполнительный директор и Covance Drug Development
Реализация опциона $138,429
12 Feb 2021
Paul R Kirchgraber
Исполнительный директор и Covance Drug Development
Реализация опциона $125,317
4 Feb 2021
Paul R Kirchgraber
Исполнительный директор и Covance Drug Development
Продажа $321,210
4 Nov 2020
Paul R Kirchgraber
Исполнительный директор и Covance Drug Development
Реализация опциона $415,703
2 Nov 2020
Paul R Kirchgraber
Исполнительный директор и Covance Drug Development
Реализация опциона $114,443
3 Apr 2020
Paul R Kirchgraber
Исполнительный директор и Covance Drug Development
Реализация опциона $108,568
12 Feb 2020
Paul R Kirchgraber
Исполнительный директор и Covance Drug Development
Реализация опциона $61,445
7 Feb 2020


Labcorp executives and stock owners

Labcorp executives and other stock owners filed with the SEC include: